Corline Biomedical: CHS Deal Finally in Place

Redeye raises its valuation of Corline following today’s announcement of the license agreement with Kardium regarding coating of the company’s ablation catheters with Corline’s CHS technology. In our initiation report, we assigned the deal an 80% probability of materializing, and we now raise our Base case to SEK 39 (35) per share. The near-term capital need is currently keeping the shares from reaching its full potential, we believe..